Share Us: Subscribe | Contact

Biblio

Export 550 results:

Tagged

Filters: Keyword is Alzheimer Disease [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

B

A. Mulak, “Bile Acids as Key Modulators of the Brain-Gut-Microbiota Axis in Alzheimer's Disease.”, J Alzheimers Dis, vol. 84, no. 2, pp. 461-477, 2021.

T. Dziedzic, Pera, J., Klimkowicz-Mrowiec, A., Mroczko, B., and Slowik, A., “Biochemical and Radiological Markers of Alzheimer's Disease Progression.”, J Alzheimers Dis, vol. 50, no. 3, pp. 623-44, 2016.

D. R. Galasko, Grill, J. D., Lingler, J. H., and Heidebrink, J. L., “A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time?”, J Alzheimers Dis, vol. 90, no. 3, pp. 963-966, 2022.

T. K. Karikari, “Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance.”, J Alzheimers Dis, vol. 90, no. 3, pp. 967-974, 2022.

I. Koychev, Jansen, K., Dette, A., Shi, L., and Holling, H., “Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis.”, J Alzheimers Dis, vol. 79, no. 1, pp. 177-195, 2021.

A. Malishkevich, Marshall, G. A., Schultz, A. P., Sperling, R. A., Aharon-Peretz, J., and Gozes, I., “Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.”, J Alzheimers Dis, vol. 50, no. 1, pp. 249-60, 2016.

F. Guillot, Kemppainen, S., Lavasseur, G., Miettinen, P. O., Laroche, S., Tanila, H., and Davis, S., “Brain-Specific Basal and Novelty-Induced Alternations in PI3K-Akt and MAPK/ERK Signaling in a Middle-Aged AβPP/PS1 Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1157-73, 2016.

H. - F. Wang, Wan, Y., Hao, X. - K., Cao, L., Zhu, X. - C., Jiang, T., Tan, M. - S., Tan, L., Zhang, D. - Q., Tan, L., and Yu, J. - T., “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration.”, J Alzheimers Dis, vol. 52, no. 1, pp. 179-90, 2016.

I. A. Clark and Vissel, B., “Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogenesis Infer New Therapeutic Approaches.”, J Alzheimers Dis, vol. 79, no. 3, pp. 931-948, 2021.

R. Benca, W Herring, J., Khandker, R., and Qureshi, Z. P., “Burden of Insomnia and Sleep Disturbances and the Impact of Sleep Treatments in Patients with Probable or Possible Alzheimer's Disease: A Structured Literature Review.”, J Alzheimers Dis, vol. 86, no. 1, pp. 83-109, 2022.

C

F. Emanuele Pozzi, Appollonio, I., Ferrarese, C., and Tremolizzo, L., “Can Traditional Board Games Prevent or Slow Down Cognitive Impairment? A Systematic Review and Meta-Analysis.”, J Alzheimers Dis, vol. 95, no. 3, pp. 829-845, 2023.

H. Khodadadi, Salles, É. Lopes, Jarrahi, A., Costigliola, V., Khan, M. B., Yu, J. C., Morgan, J. C., Hess, D. C., Vaibhav, K., Dhandapani, K. M., and Baban, B., “Cannabidiol Ameliorates Cognitive Function via Regulation of IL-33 and TREM2 Upregulation in a Murine Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 80, no. 3, pp. 973-977, 2021.

E. Aso, Andrés-Benito, P., Carmona, M., Maldonado, R., and Ferrer, I., “Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”, J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.

M. Mäkelä, Paetau, A., Polvikoski, T., Myllykangas, L., and Tanskanen, M., “Capillary amyloid-β protein deposition in a population-based study (Vantaa 85+).”, J Alzheimers Dis, vol. 49, no. 1, pp. 149-57, 2016.

A. Shafir, Ritchie, C. S., Garrett, S. B., Sideman, A. Bernstein, Naasan, G., Merrilees, J., Widera, E., Flint, L., and Harrison, K. L., “"Captive by the Uncertainty"-Experiences with Anticipatory Guidance for People Living with Dementia and Their Caregivers at a Specialty Dementia Clinic.”, J Alzheimers Dis, vol. 86, no. 2, pp. 787-800, 2022.

K. Ding, Tarumi, T., Zhu, D. C., Tseng, B. Y., Thomas, B. P., Turner, M., Repshas, J., Kerwin, D. R., Womack, K. B., Lu, H., C Cullum, M., and Zhang, R., “Cardiorespiratory Fitness and White Matter Neuronal Fiber Integrity in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 2, pp. 729-739, 2018.

M. A. Burguillos, Deierborg, T., Kavanagh, E., Persson, A., Hajji, N., Garcia-Quintanilla, A., Cano, J., Brundin, P., Englund, E., Venero, J. L., and Joseph, B., “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.

G. G. Fillenbaum and Mohs, R., “CERAD (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychology Assessment Battery: 35 Years and Counting.”, J Alzheimers Dis, vol. 93, no. 1, pp. 1-27, 2023.

S. Chaudhary, Zhornitsky, S., Chao, H. H., van Dyck, C. H., and Li, C. - S. R., “Cerebral Volumetric Correlates of Apathy in Alzheimer's Disease and Cognitively Normal Older Adults: Meta-Analysis, Label-Based Review, and Study of an Independent Cohort.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1251-1265, 2022.

D. Renard, Wacongne, A., Ayrignac, X., Charif, M., Fourcade, G., Azakri, S., Le Floch, A., Bouly, S., Marelli, C., Arquizan, C., Hirtz, C., Gabelle, A., Thouvenot, E., and Lehmann, S., “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 3, pp. 759-64, 2016.

D. - W. Chen, Wang, J., Zhang, L. - L., Wang, Y. - J., and Gao, C. - Y., “Cerebrospinal Fluid Amyloid-β Levels are Increased in Patients with Insomnia.”, J Alzheimers Dis, vol. 61, no. 2, pp. 645-651, 2018.

A. Kimura, Yoshikura, N., Hayashi, Y., and Inuzuka, T., “Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 581-588, 2018.

P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.

K. E. Melah, Lu, S. Yuan- Fu, Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Gleason, C. E., N Dowling, M., Bratzke, L. C., Rowley, H. A., Sager, M. A., Asthana, S., Johnson, S. C., and Bendlin, B. B., “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.

C. Giuseppina Bonomi, Assogna, M., Di Donna, M. Gaia, Bernocchi, F., De Lucia, V., Nuccetelli, M., Fiorelli, D., Loizzo, S., Mercuri, N. Biagio, Koch, G., Martorana, A., and Motta, C., “Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1385-1397, 2023.

Pages